Patent ID: 6248356
Filing Date: 2001-06-19
Classification: A61K

Abstract:
A method for treating a patient with cancer, said cancer being susceptible to macrophage deactivation by spermine, comprising administering an effective amount of a compound selected from the group consisting of formula I, formula II and formula III, wherein formula I comprises: ##STR21##wherein ""A"" is independently --CH.sub.2 --, --O--, --NH--, --CO--, phenyl, or pyrimidnyl;wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6, R.sub.7, R.sub.8 and R.sub.9 are each independently H, C.sub.1-6 alkyl, C.sub.1-6 alkenyl, C.sub.1-6 alkoxy, or phenyl;wherein ""X"" is a linker moiety selected from the group consisting of C.sub.2-10 alky, C.sub.2-10 alkenyl, and R.sub.10 -R.sub.11 =R.sub.10 ; wherein R.sub.10 is independently C.sub.1-4 alkyl or C.sub.2-4 alkenyl, and wherein R.sub.11 is selected from the group consisting of CO--CH.dbd., --CH.sub.2 -phenyl-CH.dbd., --CH.sub.2 -toluenyl-CH.dbd., --CH.sub.2 - pyrimidinyl- CH.dbd., and --CH.sub.2 --O--CH.dbd.;wherein formula II comprises:H.sub.2 N--B--D--B--NH.sub.2 IIwherein ""B"" is a linker moiety independently selected from the group consisting of straight or branched C.sub.1-6 alkyl, straight or branched C.sub.2-6 alkenyl, straight or branched C.sub.1-6 alkyl substituted with an amine moiety, and straight or branched C.sub.2-6 alkenyl substituted with an amine moiety;wherein ""D"" is a nitrogen-containing moiety selected from the group consisting of pyrimidinyl, piperidyl, pyridinyl, --CH--CH.sub.2 --NH.sub.2, --CH--CH.sub.2 --CH.sub.2 --NH.sub.2, --CH--NH.sub.2, and piprazinyl;wherein formula III comprises:N.tbd.C--B--D--B--D--B--C.tbd.N IIIwherein ""B"" and ""D"" are independently defined as in formula II.